- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations
Neal Shore, MD, FACS, discusses the safety profiles reported across the nadofaragene firadenovec, SunRISe-1, and NURE-COMBO trials, highlighting any unexpected toxicities observed with these novel therapies for non-muscle-invasive and muscle-invasive bladder cancer. Additionally, he reviews key limitations of the study designs or patient populations that may impact the interpretation and generalizability of the results from these trials.
EP: 1.Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC
EP: 2.SunRISe-1: Examining Combination Therapy for HR NMIBC
EP: 3.NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC
EP: 4.Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC
EP: 5.SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer
EP: 6.Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations
EP: 7.Final Insights on Current Bladder Cancer Clinical Trials
Video content above is prompted by the following question(s):
- Discuss the safety profiles reported across these three trials. Were there any new or unexpected toxicities observed with the novel therapies compared to standard treatments?
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
